Literature DB >> 35610992

Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study.

.   

Abstract

Entities:  

Year:  2022        PMID： 35610992      PMCID： PMC9122068     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  2 in total

1.  Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

Review 2.  Golimumab for the treatment of ulcerative colitis.

Authors:  Mark Löwenberg; Nanne Kh de Boer; Frank Hoentjen
Journal:  Clin Exp Gastroenterol       Date:  2014-03-12
  2 in total
  3 in total

1.  Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

2.  Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn's and Colitis Organisation: Commentary.

Authors:  David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

Review 3.  Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

Authors:  Pascal Juillerat; Maude Martinho Grueber; Roseline Ruetsch; Giulia Santi; Marianne Vuillèmoz; Pierre Michetti
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-04-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.